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Background: Pain control in chronic pancreatitis is a major challenge; the mechanisms behind 
analgesic treatment are poorly understood. This study aims to investigate the differences in pain 
sensitivity and modulation in chronic pancreatitis patients, based on their clinical response 
(responders vs nonresponders) to placebo or pregabalin treatment.
Methods: This study was part of a randomized, double-blind, placebo-controlled trial evaluating 
the analgesic effects of pregabalin and placebo in chronic pancreatitis. Post hoc, patients were 
assigned to one of four groups, ie, responders and nonresponders to pregabalin (n=16; n=15) or 
placebo (n=12; n=17) treatment. Responders were defined as patients with .30% pain reduction 
after 3 weeks of treatment. We measured change in pain sensitivity before and after the treat-
ment using electric pain detection thresholds (ePDT) in dermatomes C5 (generalized effects) 
and Ventral T10 (segmental effects). Descending endogenous pain modulation was quantified 
via conditioned pain modulation (CPM) paradigm.
Results: Sixty patients were analyzed in a per-protocol analysis. ePDT change in C5 was 
significant vs baseline and greater in pregabalin (1.3 mA) vs placebo responders (-0.1 mA; 
P=0.015). This was not so for ePDT in Ventral T10. CPM increased more in pregabalin (9%) vs 
placebo responders (-17%; P,0.001). CPM changed significantly vs baseline only for pregabalin 
responders (P=0.006).
Conclusion: This hypothesis-generating study provides the first evidence that pain relief with 
pregabalin is associated with anti-hyperalgesic effects and increased endogenous inhibitory 
modulation. No such effects were observed in patients experiencing pain relief with the placebo 
treatment. The mechanisms underlying analgesic response to placebo vs drug treatments are 
different and, together with their interactions, deserve further study.
Keywords: chronic pancreatitis, pregabalin, placebo, chronic pain treatment, quantitative 
sensory testing, central sensitization
Introduction
Morphological changes of the pancreas due to chronic pancreatitis may cause intense 
pain, necessitating surgical or endoscopic intervention. However, many patients remain 
symptomatic even after successful surgical interventions.1,2 The majority of these 
patients have a long history of treatments with opioid-based analgesic medications 
with limited effectiveness and undesirable side effects.3 A good explanation for treat-
ment failure in these patients is lacking to date. Hence, to gain a better control of pain, 
more evidence is needed on the origin of chronic pain and how this is influenced by 
pain treatment.
We performed a randomized clinical trial to evaluate the effect of pregabalin or 
placebo on pain in patients with chronic pancreatitis. We showed better pain relief in 
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the pregabalin group than in the placebo group. Interestingly, 
a significant pain reduction on average pain could also be 
observed in the placebo group.4 Secondary analysis of this 
trial confirmed that patients with chronic pancreatitis showed 
signs of altered central pain processing, which was related to 
disease stage,5 and inhibitory effects on central sensitization 
by pregabalin.6 The impact and the magnitude of placebo anal-
gesia has been described in recent studies and meta-analyses, 
and is evolving from experimental pain to clinical pain.7–10 
Analysis of the placebo effect has shown that antinociceptive 
placebo effects may be mediated by opioid receptor ligands 
and that specific brain areas are involved.11–13 However, more 
information is needed regarding the mechanisms involved in 
possible anti-hyperalgesic and analgesic placebo effects.
Our trial also showed that some patients experienced 
large pain reduction with pregabalin or placebo (responders), 
whereas some experienced hardly any pain reduction (non-
responders).14 In animal models, the variability in response 
to pain treatment was related to the activity of different 
pain pathways, eg, the inhibitory γ-aminobutyric acid-ergic 
system, or activation of excitatory N-methyl-D-aspartate 
receptors in the central nervous system.15–17 Another expla-
nation might be that ongoing nociceptive input due to the 
inflammation of the pancreas produces changes in central 
pain processing, which are no longer dependent on ongoing 
peripheral nociceptive input.18,19 Exploration of basic pain 
mechanisms in responder and nonresponder groups by quan-
titative sensory testing (QST) might also help us understand 
the variable clinical response to pain and placebo treatment 
between individual patients.
The aim of this hypothesis-generating study was to inves-
tigate the difference in pain sensitivity and modulation by 
QST in patients with chronic pancreatitis who were respond-
ers and nonresponders to placebo or pregabalin treatment. 
This study is a secondary analysis of our original randomized 
controlled trial;4 the population and the design are similar to 
one of our previous studies.14
Methods
study overview
This study was part of an investigator-initiated, double-
blind, placebo-controlled, parallel-group study of increasing 
doses of pregabalin or placebo conducted in the Nether-
lands (Department of Surgery, Radboud university medical 
center) and Denmark (Department of Gastroenterology 
and Hepatology, Aalborg University Hospital). The study 
was approved by the Ethical Committees in both the countries 
(CMO region Arnhem-Nijmegen, Nijmegen, the Netherlands 
and The local Ethics Committee North Region,  Aalborg, 
Denmark), and all patients provided written informed consent. 
This article presents a secondary and further analysis of the 
data obtained in a previous trial focusing primarily on experi-
mental (QST) end points.4 A further explanation on how this 
study relates to our trial and other sub-studies we performed 
can be found as Supplementary material.
Patients
For trial inclusion, patients needed to have chronic abdominal 
pain typical for pancreatitis (ie, dull epigastric pain more 
than 3 days per week for at least 3 months) and a diagnosis 
of chronic pancreatitis based on the Mayo Clinic diagnostic 
criteria.20 The use of a stable regime of concomitant analgesic 
medication during the trial was another inclusion criterion. 
Exclusion criteria were painful conditions other than chronic 
pancreatitis, active (or history of) major depression, allergy 
to pregabalin or any of its components, an abnormal electro-
cardiogram at screening visit, severe renal impairment, and 
pregnant or lactating patients. Only the patients completely 
complying with the described treatment protocol were ana-
lyzed in the present per-protocol analysis.
More details regarding clinical end points, ie, pain scores 
and side effects, are provided in the original manuscript of 
the main study.4
Randomization and treatment
The randomization and study procedures have been described 
in detail in the original study.4
The study consisted of a 3-week study period of 
pregabalin or placebo treatment. During the study period, 
patients received either escalating doses of pregabalin 
(300–600 mg/day) or placebo. In the case of unacceptable 
side effects, a single downward dose titration was allowed. 
When patients reached their final dosage, they had to stay 
on that regime for the remaining study period. Patients and 
those administrating study medication, assessing outcomes, 
and analyzing data were blinded to group assignment.
For the whole study period, patients were instructed not 
to change their daily pain medication. Extra pain medication 
was only allowed in the case of a painful exacerbation of their 
chronic pancreatitis.
Patients wrote down their average and maximum pain 
on a visual analog scale (VAS) in a pain diary, where 0= no 
pain and 10= worst pain imaginable.
study visits
Eligible patients were randomized for placebo or pregabalin 
on their second visit, 1 week after their screening visit. After 
randomization, all patients had a baseline QST measurement, 
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followed by another QST measurement at the end of the 
study period of 3 weeks, ie, before they were instructed to 
taper their medication.
Quantitative sensory testing
QST took place using a standard temporal test sequence. 
Testing in females was not standardized with regard to phase 
of the menstrual cycle because all female patients were 
amenorrheic. After initial training, electric pain detection 
thresholds (ePDT) to electric constant current skin stimula-
tion (Digistim; Biometer A/S, Copenhagen, Denmark; tetanic 
stimulation at 100 Hz, 0.2 ms square waves, self-adhesive 
electrodes 3 cm apart) were measured on the dominant side 
of the body at the following sites: lower neck (C5 dermatome) 
and pancreatic site (Ventral T10 dermatome) (Figure 1). The 
Ventral T10 dermatome was chosen because painful stimuli 
delivered on this skin area are likely to be processed by the 
same dorsal horn neurons onto which the nociceptive stimuli 
coming from the pancreas converge. The C5 dermatome was 
chosen as a dermatome distant from the pancreas to observe 
generalized effects on pain thresholds.18,21
The conditioned pain modulation (CPM, previously 
known as diffuse noxious inhibitory controls) paradigm was 
performed to test the ability of a patient to generate descend-
ing inhibitory pain modulation.22,23 Pressure pain tolerance 
thresholds (the test stimulus) were determined before and 
after the cold pressor task (the conditioning stimulus), and 
the CPM effect was determined in the nondominant L4 der-
matome (quadriceps muscle 5 cm proximal to the patella) as 
the relative change (%) in pressure pain tolerance thresholds. 
For the cold pressor task, the dominant hand was immersed 
in ice-chilled water (1.0°C±0.3°C) continuously stirred by 
a pump. The patient was told to remove the hand from the 
water after 2 minutes of immersion, or sooner if the pain was 
considered to be intolerable, and the immersion time noted. 
Immediately after the cold pressor task, the subjects rated the 
pain experienced during the test by using a VAS for quality 
control purposes.18
Outcome measures
Changes in the following parameters (baseline values vs 
values after 3 weeks of the study medication) were the end 
points of our study:
1. ePDT for dermatomes C5 and Ventral T10
2. CPM response.
We chose ePDT as a QST end point for altered pain sen-
sitivity based on publications describing QST measurements 
before and after pregabalin treatment. These publications 
showed a strong ePDT response when measurements were 
compared before and after pregabalin treatment in chronic 
pancreatitis.6,14
Patient groups
Patients in the pregabalin and placebo groups with more than 
30% pain reduction on their average daily VAS score after 
3 weeks of study medication vs baseline values were defined 
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Figure 1 Dermatomes of measurement for quantitative sensory testing.
Notes: Quantitative sensory testing was performed on the following sites on the 
dominant body side (closed dots): lower neck (c5 dermatome) and upper abdominal 
area (Ventral T10 dermatome). conditioned pain modulation was determined in the 
nondominant l4 dermatome (open dot).
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as responders. Patients with 30% or less pain reduction on their 
average daily VAS score after 3 weeks of study medication 
were defined as nonresponders. The cut-off point was based on 
clinical pain studies using a numeric rating scale or VAS.4,14,24,25 
On the basis of study medication and pain reduction, four 
treatment groups of patients were thus defined: 1) responder 
placebo group, 2) nonresponder placebo group, 3) responder 
pregabalin group, and 4) nonresponder pregabalin group.
statistical analysis
A pre hoc power calculation based on QST as an end point 
was not performed because the study was a part of a random-
ized clinical trial that investigated pregabalin, powered for a 
clinical primary end point, ie, change in clinical pain score. 
For this mechanistic study, we performed a per-protocol 
analysis.
All baseline characteristics and measurements are given 
as medians with interquartile ranges (IQRs), unless men-
tioned otherwise.
We performed statistical analysis using Statistica for 
Windows Software Package (Release 7.0; StatSoft Inc., Tulsa, 
OK, USA). Statistical significance was set at P#0.05.
Baseline characteristics were compared between the 
groups with Kruskal–Wallis one-way analysis of variance 
with post hoc analysis using Mann–Whitney U test.
Analysis of incidence of responders and nonresponders 
within the population was performed by chi-square test.
Within the four treatment groups, baseline values and 
values after 3 weeks of study medication were analyzed 
by Wilcoxon signed-rank test for ePDT in the individual 
dermatomes and CPM response.
Among the four treatment groups, baseline values and 
their change after 3 weeks’ treatment were compared using 
the Kruskal–Wallis one-way analysis of variance with post 
hoc analysis using Mann–Whitney U test for ePDT in the indi-
vidual dermatomes and CPM response. Four subgroups com-
parisons were performed: 1) placebo responders vs placebo 
nonresponders, 2) placebo responders vs pregabalin respond-
ers, 3) placebo nonresponders vs pregabalin nonresponders and 
4) pregabalin responders vs pregabalin nonresponders.
Subgroup (post hoc) analysis was conservatively Bonfer-
roni corrected for multiple comparisons (three comparisons, 
P#0.016).
Results
enrollment and baseline characteristics
From October 2008 to May 2010, a total of 236 patients were 
screened and 64 patients were randomized. Sixty patients 
completed the study according to the treatment protocol 
and were included in the final analysis (Figure 2). All 
the patients (23 women, 37 men; median age 53 years [IQR 
46–62]) had pain due to chronic pancreatitis and were on 
a stable analgesic therapy. The average daily VAS score of 
all the patients before the start of trial medication was 4 
(IQR 2–5), and their maximum daily VAS score was 5 (IQR 
4–7). Their median opioid consumption was 60 mg (IQR 
9–146) of morphine equivalents per day. Demographic data 
of all the four patient groups are provided in Table 1. The 
data showed no significant differences, except for VAS after 
3 weeks of study treatment.
Pain characteristics
The medians of the average and maximum VAS scores 
in the pain diaries were comparable at baseline for all (four) 
the treatment groups. Moreover, the pain medication and 
morphine equivalents per day were comparable at baseline. 
The incidence of responders and nonresponders did not differ 
significantly among all 60 patients and within the placebo or 
pregabalin group (Table 1).
Within the treatment groups, both the responder groups 
showed a decline in the average and maximum VAS score 
after 3 weeks of study treatment (less pain); this was 
significant for the responder placebo group for average 
(P=0.003) and maximum (P=0.003) VAS scores and for 
the pregabalin responder group for average (P=0.001) and 
maximum (P=0.001) VAS scores (Table 1). The median 
percentage reduction in average VAS score after 3 weeks 
of study treatment was 75% (IQR 54–100) for the placebo 
responder group and 69% (IQR 48–94) for the pregaba-
lin responder group. Among all the treatment groups, 
these results were significantly different compared with the 
nonresponder placebo and pregabalin groups (P#0.001) 
(Table 1).
ePDT in individual dermatomes
At baseline, ePDT in the C5 and Ventral T10 dermatomes 
was comparable between the treatment groups. Within the 
treatment groups, only pregabalin responders showed a 
significant increase in ePDT (less hyperalgesia following 
pregabalin treatment) for the C5 dermatome (P=0.009) and 
Ventral T10 dermatome (P=0.009) (Table 2).
C5 dermatome (widespread hyperalgesia): Changes in 
ePDT for the C5 dermatome were significantly different 
among the four treatment groups overall (H=10.63, P=0.014). 
Post hoc analysis showed that the pregabalin responder group 
differed significantly (less hyperalgesia following pregabalin 
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Assessed for eligibility (n=236)
Excluded (n=172)
Excluded (n=3) Excluded (n=1)
Allocated to placebo (n=30)
1. Not meeting inclusion criteria (n=135)
1. No data after study treatment (n=2)
1. No data after study treatment (n=1)
2. Missing pain diary data (n=1)
Included in per protocol analysis 
(n=31)
Included in per protocol analysis 
(n=29)
2. Declined to participate (n=27)
3. Other reasons (n=10)
Randomized (n=64)
Allocated to pregabalin (n=34)
Figure 2 study enrollment and randomization.
Note: The majority of patients “not meeting inclusion criteria” had died, were pain free, or were no longer being treated in either of the hospitals.
treatment) from the placebo responder group (P=0.015) 
(Table 2 and Figure 3).
Ventral T10 dermatome (segmental hyperalgesia): No 
significant differences between the groups were seen for 
changes in ePDT in the Ventral T10 dermatome (H=5.14, 
P=0.162) (Table 2 and Figure 4).
conditioned pain modulation
CPM response was comparable among all the four patient 
groups at baseline. Within the groups, the pregabalin respond-
ers showed a significant increase in CPM response, ie, a more 
effective response, after 3 weeks of treatment (P=0.006). In 
contrast, the placebo responders showed a nonsignificant 
trend for a decrease in CPM response, which is a less effec-
tive response (more pro-nociceptive pain modulation), after 
3 weeks of treatment (P=0.028) (Table 2).
The changes in CPM responses were significantly 
different among the groups (H=11.3, P=0.01). Post hoc 
analysis showed that the pregabalin responders had a CPM 
response that differed significantly from that of the patients 
in the placebo responder group (P,0.001) (Table 2 and 
Figure 5).
Discussion
This is the first study to describe the relation between the 
clinical analgesic response, defined as responders and nonre-
sponders, to placebo or pregabalin treatment and changes in 
pain processing using QST measures in patients with chronic 
pancreatitis. Our study shows the presence of significant anti-
hyperalgesic effects (decrease in pain sensitivity) in pregabalin 
responders and no significant anti-hyperalgesic effects in 
placebo responders. The pregabalin responders showed signifi-
cantly more anti-hyperalgesic effects compared with pregaba-
lin nonresponders. With treatment, pregabalin responders’ 
descending pain modulation (CPM response) became signifi-
cantly more inhibitory, whereas that of placebo responders 
showed a trend toward becoming more facilitatory.
Our results indicate that both underlying mechanisms 
and the placebo effect need to be taken into account in the 
clinical management of pain in chronic pancreatitis. Firstly, 
the response to placebo analgesia was not accompanied by 
significant anti-hyperalgesia. Thus, mechanisms other than anti-
hyperalgesia appear to operate in placebo analgesia. Secondly, 
only in the pregabalin responders, pain thresholds within and 
distant from the pancreatic segment increased significantly. 
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Table 1 Demographic and clinical characteristics of patients
Placebo  
responders (n=12)
Placebo  
nonresponders (n=17)
Pregabalin  
responders (n=16)
Pregabalin  
nonresponders (n=15)
age (years) 54 (41–63) 59 (49–64) 52 (50–59) 49 (43–57)
Males, n (%) 9 (75) 10 (59) 9 (56) 9 (60)
etiology, n (%)
–  Toxic, metabolic 9 (75) 7 (41) 6 (38) 9 (60)
–  idiopathic 2 (17) 9 (53) 6 (38) 5 (33)
–  genetic 0 (0) 0 (0) 1 (6) 1 (7)
–  autoimmune 0 (0) 0 (0) 1 (6) 0 (0)
–  Recurrent and severe acute pancreatitis 0 (0) 1 (6) 1 (6) 0 (0)
–  Obstructive 1 (8) 0 (0) 1 (6) 0 (0)
Diary pain score (Vas before)
–  average pain 4 (2–5) 4 (2–5) 4 (3–5) 4 (2–7)
–  Maximum pain 5 (2–7) 5 (4–7) 6 (4–9) 7 (4–8)
Diary pain score (Vas after)*
–  average pain 1 (0–2)# 4 (2–6) 1 (0–2)# 4 (2–6)
–  Maximum pain 1 (0–4)# 5 (4–7) 2 (1–5)# 5 (4–7)
concomitant analgesics, n (%)†
–  none 2 (17) 0 (0) 2 (13) 1 (7)
–  Weak analgesics 3 (25) 8 (47) 4 (25) 3 (20)
–  strong analgesics 7 (558) 9 (53) 10 (63) 11 (73)
MeQ/day 45 (23–135) 48 (8–120) 71 (4–127) 80 (10–180)
Duration of chronic pancreatitis (months) 151 (77–212) 84 (73–112) 83 (54–131) 117 (100–166)
Diabetes mellitus, n (%) 6 (50) 4 (24) 7 (44) 3 (20)
Previous interventions for chronic pancreatitis, no (%)
–  Pancreas resection/drainage procedures 2 (17) 3 (18) 3 (19) 3 (20)
–  Thoracoscopic splanchnic denervation 1 (8) 3 (18) 0 (0) 2 (13)
– celiac blockade 1 (8) 0 (0) 1 (6) 0 (0)
enzyme treatment for pancreatic exocrine  
insufficiency, n (%)
6 (50) 6 (35) 7 (44) 8 (53)
Ongoing alcohol abuse, n (%)‡ 4 (33) 6 (35) 3 (19) 3 (20)
current smoker, n (%) 9 (75) 13 (76) 12 (80) 12 (75)
Notes: all values are medians with iQRs unless mentioned otherwise. Percentages may not total 100 due to rounding. Vas: 0–10. †Weak analgesics were defined as NSAIDs, 
paracetamol, codeine, and tramadol. Strong analgesics were defined as opioid-based therapies. “Pregabalin” is pregabalin study group and “placebo” is placebo study group; 
‡alcohol-abusing patients were defined as female patients drinking 14 units of alcohol per week or male patients drinking 21 units of alcohol per week; #a significant reduction 
in mean and maximum Vas scores was observed within the treatment group after study treatment (P-value #0.010); *statistical differences between groups where the 
placebo responders and pregabalin responders differed significantly (P-value #0.010) from the placebo nonresponders and pregabalin nonresponders.
Abbreviations: IQR, interquartile range; MEQ, morphine equivalents; NSAID, nonsteroidal anti-inflammatory drug; VAS, visual analog scale.
Table 2 Pain thresholds and cPM response at baseline, after 3 weeks’ treatment and the change in values for all the groups
Placebo  
responders (n=12)
Placebo  
nonresponders (n=17)
Pregabalin  
responders (n=16)
Pregabalin  
nonresponders (n=15)
ePDT (ma) (baseline)
– c5 3.5 (2.4–7.6) 3.5 (2.2–5.5) 3.8 (2.7–4.7) 3.6 (2.2–5.1)
– T10V 6.1 (3.5–7.8) 3.5 (2.5–6.8) 5.7 (4.5–7.6) 5.2 (4.5–10.4)
ePDT (after treatment)
– c5 5.0 (2.0–6.3) 2.3 (2.1–4.5) 4.8 (3.5–6.3)* 4.5 (3.3–5.4)
– T10V 7.0 (5.0–8.2) 3.4 (3.0–6.1) 6.8 (5.8–10.1)† 6.4 (3.9–7.5)
change ePDT
– c5 -0.1 (-1.3 to 0.5) -0.3 (-0.7 to 0.6) 1.3 (0.4–2.0) 0.4 (-0.9 to 1.3)
– T10V 0.7 (-0.6 to 1.9) -0.2 (0.8–1.2) 1.7 (0.0–3.4) -0.3 (-1.1 to 1.9)
cPM response (%) (baseline) 13 (-3 to 25) 14 (5–44) 11 (-12 to 23) 12 (-19 to 39)
cPM response (%) (after treatment) -3 (-12 to 9) 17 (-2 to 36) 15 (0–50)‡ 0 (-1 to 23)
change in cPM response (%) -17 (-35 to -6) 3 (-22 to 10) 9 (4–55) -7 (-35 to 16)
Notes: all values are medians with iQRs. c5 is the c5 dermatome (lower neck), and T10V is the ventral T10 dermatome (upper abdominal area). statistical difference 
between baseline and after treatment values: *P=0.009, †P=0.009, and ‡P=0.006.
Abbreviations: cPM, conditioned pain modulation; ePDT, electric pain detection thresholds; iQR, interquartile range.
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Distant from the pancreatic segment, this anti-hyperalgesic 
effect was significantly larger in the pregabalin respond-
ers than the nonresponders. In the pancreatic segment, the 
anti- hyperalgesic response to pregabalin treatment did not 
differ significantly between the pregabalin responders and 
nonresponders. This suggests that analgesic response to pregab-
alin treatment is linked to anti-hyperalgesic effect, although 
other mechanisms may also be operating.  Furthermore, general-
ized anti-hyperalgesic effects appear more prominent than seg-
mental anti-hyperalgesic effects. Thirdly, it would appear that 
endogenous descending pain modulation plays an important 
role in analgesic response and may be fundamentally different 
for placebo vs pregabalin treatments.
effect of pregabalin
Treatments targeting the central nervous system, eg, gabap-
entinoids or tricyclic antidepressants, are increasingly being 
demonstrated to improve the management of chronic pain 
disorders.26 For chronic pancreatitis, we have shown pregabalin 
to be effective in reducing pain scores after 3 weeks of treat-
ment together with a positive overall treatment response as 
rated by patients.4 Accompanying the clinical effect, we found 
an anti-hyperalgesic effect of pregabalin for electric stimuli.6 
The present study further elucidates these results by show-
ing that anti-hyperalgesic effects in responders to pregabalin 
are significant, particularly in a dermatome distant from the 
pancreas. The overall size of the effect in the pancreatic seg-
ment was comparable between the pregabalin responders and 
nonresponders. In another study, we showed that patients with 
chronic pancreatitis with segmental hyperalgesia had a superior 
clinical response to pregabalin.27 Taken together, these results 
suggest that the major anti-hyperalgesic effect of pregabalin is 
on ascending spinal sensitization rather than directly on sensi-
tization within the pancreatic spinal segment. Clearly, further 
research is needed regarding the sites of action of pregabalin 
within the nervous system. Although baseline CPM values 
were similar, modulatory responses were greater and signifi-
cantly inhibitory in pregabalin (vs placebo) responders. This 
outcome could be construed as a direct, anti-facilitatory effect 
of pregabalin on CPM, or an indirect one based on the reduction 
of ascending central nociceptive transmission.22 If pregabalin 
affects ascending central pathways, it might also affect descend-
ing ones, an explanation that could support direct effects on 
CPM. A further possible explanation could be other differences 
between the pregabalin responder and nonresponder patients, 
ie, regarding the use of more strong analgesics or a history of 
more pain reducing previous interventions.
Studies on the effects of centrally active medication, 
eg, pregabalin, gabapentin, or S-ketamine, on central 
sensitization are limited.18,28–33 They demonstrate reduction 
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of hyperalgesia (central sensitization), in accordance with 
our study. None of these studies investigated differences 
between placebo and drug responders, and none studied 
pain modulation (CPM). Responders and nonresponders to 
gabapentin have been described in a rat study, where rats with 
selective nerve injury (spinal level) showed differences in 
descending inhibition. The extent of suggested changes in the 
central nervous system may predict the effect of pregabalin 
and gabapentin treatment.34
effect of placebo
The placebo effect on clinical pain has been described 
extensively.35–37 Imaging studies of the brain have shown 
increased activity in pain-related areas during painful stimuli 
and placebo analgesia.38 A relation has been demonstrated 
between desire for pain relief or expected pain levels and 
opioid-related activity in certain brain areas. These psycho-
logical factors and placebo effect can be antagonized by 
naloxone.39 The effect of placebo analgesia appears to be 
highly variable and depends on contextual factors.11,40,41 In 
our clinical study, we found a strong placebo response, for the 
whole group, albeit significantly lower than that with pregaba-
lin treatment.4 This placebo response may be explained by 
the psychosocial context and in the suggestion of treatment 
effect.36,37,42 Patients with chronic pancreatitis, with their 
extensive medical history, their expectation or desire for pain 
relief, and the possibility of being randomized for pregabalin, 
may be particularly susceptible to placebo effects.
Our study showed that the placebo responders had a 
significant strong clinical effect on clinical pain compared 
with the placebo nonresponders. However, we also demon-
strated no significant anti-hyperalgesic effects for both the 
responders and nonresponders to placebo. As effects on skin 
pain sensitivity were similar in the placebo responders and 
nonresponders, central anti-hyperalgesia is unlikely to be the 
mechanism underlying placebo analgesia, at least in patients 
with chronic pancreatitis. Furthermore, a trend for a decrease 
in inhibitory CPM response was seen only in the placebo 
responders. Theoretically, this finding could be linked to a 
negative interaction of placebo effect with CPM. This unex-
pected trend result further suggests that anti-hyperalgesia is 
not a major mechanism underlying analgesia in this context. 
Clearly, more research is necessary.
Limitations
A limitation of this study is the relatively small size of the four 
patient groups. Nevertheless, significant differences could 
be observed among the groups. Furthermore, we may have 
introduced bias by using a per-protocol analysis. However, 
we think that analyzing only the patients who fully complied 
to the study protocol, ie, used all their study medications and 
had measurements after study treatment, is the proper way 
to investigate mechanisms in responders and nonresponders 
to the trial medication. It should be noted that the majority 
of the patients in both the study arms were compliant and 
all study medications were taken correctly. The duration of 
study medication in the initial trial was 3 weeks; perhaps, a 
longer study period would have given a more distinct differ-
ence between both the groups. In our clinical study, 39% of 
pregabalin patients did not tolerate 300 mg pregabalin twice 
daily, and were treated with 150 mg twice daily. The distri-
bution of patients not tolerating 300 mg twice daily was not 
significantly different between the pregabalin responders and 
nonresponders. Perhaps, in a larger population, this differ-
ence could be of significance. Another source of bias could 
have been that the groups were not comparable at baseline 
for factors we did not measure, ie, expectations regarding 
study effect or other psychological measures. However, this 
seems unlikely because no significant differences could be 
found in the clinically relevant baseline characteristics among 
the four groups. Moreover, no differences in baseline values 
were found for use of strong analgesics, morphine equiva-
lents, prevalence of diabetes mellitus, nicotine exposure, or 
alcohol consumption (possible confounding effects on pain 
perception) among all the four groups.
Because chronic pancreatitis is predominantly a visceral 
pain syndrome, we could have introduced bias by only analyz-
ing electric stimulation (somatic skin pain) and not pressure 
stimulation (deep tissue and visceral pain) in this study. The rea-
son we chose to analyze only electrical stimulation was based 
on earlier study results,6 where electrical stimulation was the 
earliest and most sensitive parameter of change in pain sensi-
tization due to medication in patients with chronic pancreatitis. 
In this study, we found that the anti-hyperalgesic effect of 
pregabalin resulted in a greater increase of electric pain 
thresholds than that of pressure pain thresholds after 3 weeks 
of treatment.6 This is probably because the skin, in comparison 
with deep and visceral tissue, is a tissue that is constantly and 
highly subject to sensory modulation by the central nervous 
system. Thus, changes in central sensitization will likely first 
be reflected in skin projection areas of the spinal dorsal horn 
neurons sensitized by the chronic pancreatitis.43
Conclusion
Our study provides evidence that patients treated with pla-
cebo show no anti-hyperalgesic effects paralleling pain relief 
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after a treatment period of 3 weeks in chronic pancreatitis. 
Patients with a positive effect on clinical pain following 
pregabalin treatment were the only ones to show significant 
anti-hyperalgesic effects, particularly in the dermatome dis-
tant from the pancreas, with comparable anti-hyperalgesic 
effects for pregabalin responders and nonresponders in the 
pancreatic dermatome itself. The pregabalin responders 
showed an increase in endogenous inhibitory modulation 
compared with a trend to decrease in the placebo responders. 
Both the existence of a potent placebo effect and the difference 
between responders and nonresponders regarding underlying 
pain sensitivity and modulation need to be taken into account 
in the management of pain in chronic pancreatitis.
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Supplementary material
The present study is a hypothesis-generating and an explor-
atory analysis of experimental end points of our clinical trial 
using pregabalin and placebo in chronic pancreatitis.1 One of 
our earlier studies describing these experimental end points 
showed that our patients with chronic pancreatitis were hyper-
algesic, and this could be related to disease stage based on the 
Mannheim severity index.2 Later, we described the effect of 
pregabalin on pain processing in chronic pancreatitis. Only 
the patients randomized for pregabalin were analyzed, and it 
was shown that pregabalin has moderate inhibitory effects on 
central sensitization, manifest as spreading hyperalgesia in 
patients with chronic pancreatitis.3 In another study, we exam-
ined whether quantitative sensory testing (QST) could predict 
the clinical effect of pregabalin and placebo. Study results 
showed that QST predicts the analgesic effect of pregabalin 
in patients with painful chronic pancreatitis.4 Another sub-
study of our clinical trial described end points based on or 
analyzed with electroencephalography and QST.5,6
What makes the present study different from the previ-
ously performed studies?
1. We described responders and nonresponders to placebo 
or pregabalin treatment.
2. We did not aim at clinical end points, ie, pain relief, but 
at an experimental end point, pain processing.
3. We investigated the difference in pain sensitivity and mod-
ulation by QST before and after study treatment, together 
with the change in pain sensitivity and modulation.
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